Contact John

Speaking Engagements

  

With the ever-increasing competitive nature of the ADC field, target selection is a key differentiator between having a failed or successful ADC. Being able to optimally triangulate the choice of linker-payload, target and indication is vital in developing an ADC that can have the biggest impact on patients.

06-08 December 2022
  

Join us at the 14th World ADC San Diego conference, where the revolutionary field of antibody-drug conjugates (ADCs) continues to make remarkable strides in the oncology landscape. In the year 2023, the ADC renaissance reaches new heights with the eagerly anticipated approval of ImmunoGen's ELAHERE, marking the ninth ADC to receive regulatory clear

16-19 October 2023